Common use of Notification and Meeting Clause in Contracts

Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations under Sections 3.9.1, 3.9.2 or 3.9.3, then CombinatoRx shall so notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within thirty (30) days after such written notice to discuss in good faith for a period of not more than twenty-one (21) days CombinatoRx's concerns and Fovea's development plans with respect to the Collaboration Combinations.

Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations under Sections 3.9.1Section 4.1.1, 3.9.2 4.1.2 or 3.9.34.1.5, then CombinatoRx shall so notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within thirty fifteen (3015) days after such written notice to discuss in good faith for a period of not more than twenty-one seven (217) days CombinatoRx's ’s concerns and Fovea's ’s development plans or commercialization activities with respect to the Collaboration Licensed Combinations.

Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations under Sections 3.9.1, 3.9.2 Section 4.5.1 or 3.9.34.5.2, then CombinatoRx shall so notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within thirty (30) days after such written notice to discuss in good faith for a period of not more than twenty-one (21) days CombinatoRx's concerns and Fovea's development plans with respect to the Collaboration Licensed Combinations.

Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations under Sections 3.9.13.3.1, 3.9.2 3.3.2, 3.3.3 or 3.9.33.3.5, then CombinatoRx shall so notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within thirty fifteen (3015) days after such written notice to discuss in good faith for a period of not more than twenty-one fifteen (2115) days CombinatoRx's concerns and Fovea's development plans activities with respect to the Collaboration Combinations.

Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations under Sections 3.9.1, 3.9.2 3.3.1 or 3.9.33.3.3, then CombinatoRx shall so notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within thirty fifteen (3015) days after such written notice to discuss in good faith for a period of not more than twenty-one fifteen (2115) days CombinatoRx's concerns and Fovea's development plans activities with respect to the Collaboration CombinationsCombination.

Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations to use Commercially Reasonable Efforts to achieve the milestones described under Sections 3.9.1, 3.9.2 Section 4.1.1 or 3.9.34.1.3, then CombinatoRx shall so notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within thirty fifteen (3015) days after such written notice to discuss in good faith for a period of not more than twenty-one seven (217) days CombinatoRx's ’s concerns and Fovea's ’s development plans activities with respect to the Collaboration Licensed Combinations.